Principal Financial Group Inc. Reduces Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Principal Financial Group Inc. lowered its holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 8.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 104,678 shares of the company’s stock after selling 9,164 shares during the period. Principal Financial Group Inc.’s holdings in Fulgent Genetics were worth $2,272,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Asset Management One Co. Ltd. boosted its stake in shares of Fulgent Genetics by 60.8% during the 4th quarter. Asset Management One Co. Ltd. now owns 2,039 shares of the company’s stock valued at $61,000 after buying an additional 771 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Fulgent Genetics by 34.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,569 shares of the company’s stock worth $190,000 after purchasing an additional 1,667 shares during the period. Teza Capital Management LLC bought a new stake in Fulgent Genetics in the third quarter valued at $200,000. Louisiana State Employees Retirement System acquired a new position in shares of Fulgent Genetics during the fourth quarter valued at $292,000. Finally, Illinois Municipal Retirement Fund grew its position in shares of Fulgent Genetics by 5.6% during the fourth quarter. Illinois Municipal Retirement Fund now owns 12,534 shares of the company’s stock worth $362,000 after acquiring an additional 668 shares during the last quarter. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Trading Down 0.7 %

NASDAQ:FLGT traded down $0.13 during mid-day trading on Friday, hitting $19.80. The stock had a trading volume of 24,886 shares, compared to its average volume of 185,283. Fulgent Genetics, Inc. has a 52 week low of $18.91 and a 52 week high of $44.09. The company has a 50 day simple moving average of $20.79 and a 200-day simple moving average of $23.26.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings results on Friday, May 3rd. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.20. Fulgent Genetics had a negative return on equity of 2.92% and a negative net margin of 57.72%. The company had revenue of $64.49 million for the quarter, compared to analysts’ expectations of $65.74 million. Sell-side analysts anticipate that Fulgent Genetics, Inc. will post -2.12 earnings per share for the current year.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.